title: Pegylated arginase I: a potential therapeutic approach in T-ALL.
abstract: Adult patients with acute lymphoblastic T cell leukemia (T-ALL) have a very poor prognosis and few effective therapeutic options. Therefore, novel therapies that increase the efficacy of the treatments and that prolong T-ALL patient survival are needed. Malignant T cells require high concentrations of nutrients to sustain their increased rate of proliferation. In this study, we determined whether L-Arginine depletion by the pegylated form of the L-Arginine-metabolizing enzyme arginase I (peg-Arg I) impairs the proliferation of malignant T cells. Our results show that peg-Arg I depleted L-Arginine levels in vitro and in vivo. In addition, treatment of malignant T-cell lines with peg-Arg I significantly impaired their proliferation, which correlated with a decreased progression into the cell cycle, followed by the induction of apoptosis. Furthermore, peg-Arg I impaired the expression of cyclin D3, a fundamental protein in T-ALL proliferation, through a global arrest in protein synthesis. Injection of peg-Arg I plus chemotherapy agent Cytarabine prolonged survival in mice bearing T-ALL tumors. This antitumoral effect correlated with an inhibition of T-ALL proliferation in vivo, a decreased expression of cyclin D3, and T-ALL apoptosis. The results suggest the potential benefit of L-Arginine depletion by peg-Arg I in the treatment of T-cell malignancies.
authors.affiliation: Tumor Immunology Program, Stanley S. Scott Cancer Center, Louisiana State University-Health Sciences Center (LSU-HSC), New Orleans, LA 70112, USA.
authors.forename: Claudia P
authors.initials: CP
authors.lastname: Hernandez
authors.forename: Kevin
authors.initials: K
authors.lastname: Morrow
authors.forename: Lluis A
authors.initials: LA
authors.lastname: Lopez-Barcons
authors.forename: Jovanny
authors.initials: J
authors.lastname: Zabaleta
authors.forename: Rosa
authors.initials: R
authors.lastname: Sierra
authors.forename: Cruz
authors.initials: C
authors.lastname: Velasco
authors.forename: John
authors.initials: J
authors.lastname: Cole
authors.forename: Paulo C
authors.initials: PC
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001119:Arginase / Q000494:pharmacology* / Q000627:therapeutic use; D001120:Arginine / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D056743:Cyclin D3 / Q000378:metabolism; D003561:Cytarabine / Q000494:pharmacology; D018572:Disease-Free Survival; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D011092:Polyethylene Glycols; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D015996:Survival Rate; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; C534696:CCND3 protein, human; D056743:Cyclin D3; D003561:Cytarabine; D011092:Polyethylene Glycols; D001120:Arginine; D001119:Arginase
references.citation: Nat Rev Mol Cell Biol. 2009 Jun;10(6):430-6
references.pmid: 19461665
references.citation: Cell Cycle. 2007 Nov 15;6(22):2768-72
references.pmid: 17986863
references.citation: Trends Immunol. 2003 Jun;24(6):302-6
references.pmid: 12810105
references.citation: Cell. 2006 Jun 16;125(6):1111-24
references.pmid: 16777601
references.citation: J Nutr. 2004 Oct;134(10 Suppl):2760S-2764S; discussion 2765S-2767S
references.pmid: 15465781
references.citation: Blood. 2002 Mar 15;99(6):1986-94
references.pmid: 11877270
references.citation: Cancer Res. 2007 Jan 1;67(1):309-17
references.pmid: 17210712
references.citation: Cancer Res. 2005 Apr 15;65(8):3044-8
references.pmid: 15833831
references.citation: J Clin Oncol. 2004 Oct 15;22(20):4075-86
references.pmid: 15353542
references.citation: Cancer Res. 2009 Feb 15;69(4):1553-60
references.pmid: 19201693
references.citation: Cell Death Differ. 2004 Apr;11(4):381-9
references.pmid: 14685163
references.citation: Cancer Lett. 2009 May 8;277(1):91-100
references.pmid: 19138817
references.citation: Leukemia. 2000 Jul;14(7):1215-24
references.pmid: 10914545
references.citation: Cancer Res. 1979 Oct;39(10):3893-6
references.pmid: 383278
references.citation: Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):45-51
references.pmid: 15090903
references.citation: J Immunol. 2003 Aug 1;171(3):1232-9
references.pmid: 12874210
references.citation: N Engl J Med. 1998 Aug 27;339(9):605-15
references.pmid: 9718381
references.citation: Nat Rev Immunol. 2005 Aug;5(8):641-54
references.pmid: 16056256
references.citation: Blood. 2009 Feb 19;113(8):1689-98
references.pmid: 19001083
references.citation: Trends Genet. 2000 Oct;16(10):469-73
references.pmid: 11050335
references.citation: Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70
references.pmid: 8577715
references.citation: Cancer Cell. 2003 Dec;4(6):451-61
references.pmid: 14706337
references.citation: Semin Oncol. 1997 Feb;24(1):70-82
references.pmid: 9045306
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7660-8
references.pmid: 16234528
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5335-41
references.pmid: 15328169
references.citation: Blood. 2007 Feb 15;109(4):1568-73
references.pmid: 17023580
references.citation: Leuk Res. 1992;16(5):475-83
references.pmid: 1625473
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4843-8
references.pmid: 12655043
references.citation: Cell Immunol. 2004 Nov-Dec;232(1-2):21-31
references.pmid: 15922712
references.citation: J Exp Med. 2005 Oct 3;202(7):931-9
references.pmid: 16186186
references.citation: Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27
references.pmid: 15803138
references.citation: Cancer Res. 2004 Aug 15;64(16):5839-49
references.pmid: 15313928
references.citation: J Clin Oncol. 2004 May 15;22(10):1815-22
references.pmid: 15143074